辐射诱导溶瘤腺病毒联合放疗对宫颈癌细胞HeLa S3的作用效果  

Effect of radiation-induced oncolytic adenovirus combined with chemotherapy on cervical cancer HeLa S3 cells

作　　者：李笑梅[1,2] 王海波[2] 黄建[2] 

机构地区：[1]上海健康职业技术学院生物化学教研室,上海200237 [2]上海交通大学医学院生物化学与分子生物学教研室,上海200025

出　　处：《中国肿瘤生物治疗杂志》2011年第6期641-646,共6页Chinese Journal of Cancer Biotherapy

基　　金：国家自然科学基金资助项目(No.10979034;No.31071228);上海市自然科学基金资助项目(No.09ZR1416400)~~

摘　　要：目的:构建受辐射诱导的EGR-1启动子调控的携带人TRAIL基因的新型溶瘤腺病毒Ad-EGR-TRAIL,研究其联合放疗对宫颈癌细胞株HeLa S3的杀伤效果。方法:构建重组腺病毒Ad-EGR-TRAIL,用腺病毒Ad-GFP检测对HeLa S3细胞的感染效率。CCK-8法检测Ad-EGR-TRAIL组、单纯放疗组以及Ad-EGR-TRAIL联合放疗组对HeLa S3细胞的杀伤效应,同时观察它们对人正常宫颈细胞的作用。结果:成功构建腺病毒Ad-EGR-TRAIL,当MOI为100时,HeLa S3细胞的腺病毒感染效率最高。单纯Ad-EGR-TRAIL或放疗对HeLa S3细胞增殖的抑制率分别为(8.07±3.02)%和(23.02±4.03)%,Ad-EGR-TRAIL联合放疗对HeLa S3细胞增殖的抑制率达(79.77±9.15)%;同样的处理对正常宫颈细胞无明显抑制作用。结论:Ad-EGR-TRAIL联合放疗对宫颈癌细胞HeLa S3有显著的杀伤作用。Objective： To construct a new radiation-induced, EGR-1 promotor-regulated, human TRAIL gene containing oncolytic adenovirus Ad-EGR-TRAIL, and to investigate the cytotoxicity effect of Ad-EGR-TRAIL combined with chemotherapy on cervical cancer HeLa S3 cells. Methods： Recombinant adenovirus Ad-EGR-TRAIL was constructed. HeLa S3 cells were infected with Ad-GFP, and infection efficiency was observed. The cytotoxicity effect of Ad- EGRTRAIL, radiotherapy （RAD）, and Ad-EGR-TRAIL ＋ RAD on HeLa S3 cells, as well as on normal human cervical ceils, was examined by CCK-8 method. Results： Recombinant adenovirus Ad-EGR-TRAIL was successfully constructed. Ad-EGR-TRAIL showed the highest infection efficiency at MOI = 100 in HeLa S3 cells. The inhibitory rates of HeLa S3 ceils were （8.07± 3.02） % and （23.02 ±4.03 ）% when Ad-EGR-TRAIL or RAD was used alone; however, the inhibitory rate reached （79.77±9.15）% when Ad-EGR-TRAIL and RAD were used in combination; and normal cervical cells did not significantly respond to the combination Ad-EGR-TRAIL and RAD therapy. Conclusion： Ad-EGR-TRAIL combined with chemotherapy can significantly kill cervical cancer HeLa S3 cells.

关 键 词：TRAIL 腺病毒 基因疗法 放射治疗 凋亡 

分 类 号：R737.33[医药卫生—肿瘤] R730.5[医药卫生—临床医学]